1. Cytoskeleton
  2. Gap Junction Protein
  3. Larazotide acetate

Larazotide acetate 

製品番号: HY-106268A 純度: 99.68%

Larazotide acetate is a synthetic peptide. Larazotide acetate acts as a tight junction regulator and reverses leaky junctions to their normally closed state.


Larazotide acetate 構造式

Larazotide acetate 構造式

CAS 番号 : 881851-50-9

容量 価格(税別) 在庫状況 数量
10 mM * 1 mL in Water USD 138 在庫あり
Estimated Time of Arrival: December 31
1 mg USD 50 在庫あり
Estimated Time of Arrival: December 31
5 mg USD 100 在庫あり
Estimated Time of Arrival: December 31
10 mg USD 160 在庫あり
Estimated Time of Arrival: December 31
25 mg USD 320 在庫あり
Estimated Time of Arrival: December 31
50 mg   お問い合わせ  
100 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください


Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • 生物活性

  • プロトコル

  • 純度とドキュメンテーション

  • 参考文献

  • カスタマーレビュー


Larazotide acetate is a synthetic peptide. Larazotide acetate acts as a tight junction regulator and reverses leaky junctions to their normally closed state[1].

IC50 & Target

Paracellular permeability[1]


Larazotide acetate inhibits the redistribution and rearrangement of zonula occludens-1 (ZO-1) and actin caused by AT-1002 and gliadin fragments in Caco-2 and IEC6 cells. Larazotide acetate inhibits the AT-1002-induced TEER reduction and TJ opening in Caco-2 cells. Larazotide acetate inhibits the translocation of a gliadin 13-mer peptide, which has been implicated in celiac disease, across Caco-2 cell monolayers. Further, apically applied Larazotide acetate inhibits the increase in TJ permeability elicited by basolaterally applied cytokines[1].


When tested in vivo in gliadin-sensitized HLA-HCD4/DQ8 double transgenic mice, larazotide acetate inhibits gliadin-induced macrophage accumulation in the intestine and preserved normal tight junction structure[1].





CAS 番号



O=C([[email protected]](C(C)C)NC([[email protected]](CC(C)C)NC([[email protected]](C(C)C)NC(CNC(CN)=O)=O)=O)=O)N[[email protected]@H](CCC(N)=O)C(N1[[email protected]@H](CCC1)C(NCC(O)=O)=O)=O.CC(O)=O


Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years
In solvent -80°C 6 months
  -20°C 1 month
溶剤 & 溶解度

H2O : 16.67 mg/mL (21.21 mM; Need ultrasonic)

DMSO : 3.2 mg/mL (4.07 mM; Need ultrasonic and warming)

Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.2724 mL 6.3622 mL 12.7244 mL
5 mM 0.2545 mL 1.2724 mL 2.5449 mL
10 mM 0.1272 mL 0.6362 mL 1.2724 mL
*Please refer to the solubility information to select the appropriate solvent.

Caco-2 cells are seeded onto 12-well plate and grown for 21–28 days until fully differentiated. The apical and basolateral compartments of Caco-2 cell monolayers are pre-incubated in Hank’s Balanced Salt Solution (HBSS) at 37°C for 30 min. Treatment solutions containing 7.5 mM LY with or without AT-1002 (7 mM) and different concentrations of larazotide acetate (5, 10, 12.5, 15 mM) in HBSS are added to the apical compartment of each monolayer and incubated at 37°C, 50 rpm for 180 min. At the end of the incubation, samples are removed from the basolateral compartment and analyzed in a fluorescence plate reader at excitation and emission wavelengths of 485 nm and 535 nm, respectively. The increase in LY passage is calculated for each treatment and is expressed relative to that of untreated controls[1].

MCE はこれらの方法の精度を確認していません。 こちらは参照専用です。



Cohorts of HLA-HCD4/DQ8 mice (n=10 each) are sensitized (i.p.) with 500 μg of gliadin dissolved in 0.02 mM acetic acid in 50 μg of Complete Freund’sAdjuvant; thereafter, mice are gavaged with gliadin (2 mg/mouse), +/− treatment, 2×/week for 7 weeks. Group 1 receives larazotide acetate (250 μg/mouse) and gliadin, Group 2 receives AT-1002 (250 μg/mouse) and gliadin, and Group 3 is gavaged with gliadin only. A group of non-sensitized controls (CFA, i.p. only) is gavaged with rice. Twenty-four hours after the last gavage, small intestinal tissue is mounted in Ussing chambers for the measurement of electrical parameters (Isc, conductance) and macromolecule transport (horseradish peroxidase [HRP] flux). Tissue is processed for macrophage counts by immunohistochemistry using F4/80 antibody specific for a macrophage-restricted cell surface glycoprotein[1].

MCE はこれらの方法の精度を確認していません。 こちらは参照専用です。


純度: 99.68%

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • モル濃度カルキュレーター

  • 希釈カルキュレーター

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2


LarazotideGap Junction ProteinInhibitorinhibitorinhibit



Your information is safe with us. * Required Fields.




お名前 *


PC 用メールアドレス *

電話番号 *


勤務先/学校名 *

Department *


カスタマ需要量 *

国会或いは地域 *





Inquiry Information

Larazotide acetate
MCE 日本正規代理店: